Actinium Pharmaceuticals
New York
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $106.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2020)
- Ticker: nysemkt:ATNM
- Website: actiniumpharmaceuticals.com
- Phone: +1-646-459-4201
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/actinium-pharmaceuticals-4238 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.